HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $35.
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $35.